Health & Medicine

Diseases & Treatments

Covid-19 vaccine, British pharmaceutical group AstraZeneca

Émission

Le 19h30
09 September 2020

Claire-Anne Siegrist

HUG

Médecine, UNIGE

The vaccine developed in Great Britain caused an unexplained illness in a participant in the test phase, which has been suspended.

Related interventions

Sections

Health & Medicine

Diseases & Treatments

Average efficacy of 70% for AstraZeneca's vaccine

- Giuseppe Pantaleo
  
  CHUV | UNIL

23 November 2020

Sections

Health & Medicine

Diseases & Treatments

Several countries suspend use of AstraZeneca vaccine

- Claire-Anne Siegrist
  
  HUG | UNIGE

11 March 2021

Sections

Health & Medicine

Diseases & Treatments

Update on new vaccines approved in Switzerland

- Blaise Genton
  
  CHUV | UNIL

04 February 2021

Sections

Health & Medicine

Diseases & Treatments

AstraZeneca vaccine cleared by European regulator

- Blaise Genton
  
  CHUV | UNIL

29 January 2021

Sections

Health & Medicine

Diseases & Treatments

Mutations do not call vaccine efficacy into question

- Claire-Anne Siegrist
  
  HUG | UNIGE

19 December 2020

Sections

Health & Medicine

Diseases & Treatments

A technique to validate the safety and efficacy of an Ebola vaccine

- Angela Huttner
  
  HUG

13 April 2017

Sections

Health & Medicine

Diseases & Treatments

A new hepatitis C vaccine

- Francesco Negro
  
  HUG | UNIGE

23 July 2015

Sections

Health & Medicine

Diseases & Treatments

Delivery delays hamper vaccination in poor countries

- Blaise Genton
  
  CHUV | UNIL

15 June 2021